ARMISTICE CAPITAL LLC
Q4 2022 Form 13-F
NEW YORK, NEW YORK
CIK 0001601086
· CRD 168978
· SEC-registered investment adviser
$5.7B Reported Value Total
ARMISTICE CAPITAL LLC reports 3 total accounts under management (AUM). There are 3 discretionary accounts valued at $5,555,432,880, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
1 fund
· $4.7B gross asset value
Hedge Fund: $4.7B
Source: Form ADV filed 2026-03-31
Reported value
$5.7B
Quarter over quarter
+14.0%
Holdings
191
Top-10 concentration
53.0%
Filing Structure
Reports holdings for
- Armistice Capital Master Fund Ltd. (not a 13F filer in our records) · File #028-16739 · Q4 2014 – Q1 2021
Key People
Form ADV owners & control persons
Steven Joseph Boyd
MANAGING MEMBER
Jose Yldefonso Mallonga Bautista
CHIEF COMPLIANCE OFFICER AND DEPUTY CHIEF FINANCIAL OFFICER
Anthony Joseph Cordone
CHIEF FINANCIAL OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q4 2022 13F record
Q4 2022 13F filing summary
| Period of report | December 31, 2022 |
|---|---|
| Filed | February 14, 2023 |
| Form | 13F-HR |
| Reported value | $5.7B |
| Positions | 191 |
| Change in reported value | -0.6% |
| New positions | 64 |
| Exited positions | 67 |
| Position turnover | 50.8% |
| Top-10 concentration | 53.0% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 16, 2026
|
333 | $8.2B |
|
Q2 2026 13F
Filed Aug 14, 2026
|
323 | $8.2B |
|
Q1 2026 13F
Filed May 15, 2026
|
251 | $5.6B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
357 | $8.4B |
|
Q3 2025 13F
Filed Nov 17, 2025
|
318 | $6.7B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
200 | $5.8B |
|
Q1 2025 13F
Filed May 15, 2025
|
220 | $6.7B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
227 | $7.3B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
254 | $6.3B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
250 | $7.9B |
|
Q1 2024 13F
Filed May 15, 2024
|
333 | $7.5B |
|
Q4 2023 13F
Filed Feb 13, 2024
|
290 | $7.3B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
250 | $6.5B |
|
Q2 2023 13F
Filed Aug 14, 2023
|
218 | $6.9B |
|
Q1 2023 13F
Filed May 15, 2023
|
223 | $6.9B |
|
Q4 2022 13F
Filed Feb 14, 2023
|
191 | $5.7B |
|
Q3 2022 13F
Filed Nov 14, 2022
|
194 | $5.8B |
|
Q2 2022 13F
Filed Aug 15, 2022
|
175 | $5.7B |
|
Q1 2022 13F
Filed May 16, 2022
|
139 | $5.2B |
|
Q4 2021 13F
Filed Feb 14, 2022
|
143 | $6.1B |
28 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q4 2022
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | SPY P SPDR S&P 500 ETF TR | $1.3B | 22.35% |
| 2 | IWM P ISHARES TR | $732.3M | 12.78% |
| 3 | MRTX MIRATI THERAPEUTICS INC | $158.0M | 2.76% |
| 4 | SUPN SUPERNUS PHARMACEUTICALS INC | $155.4M | 2.71% |
| 5 | TVTX TRAVERE THERAPEUTICS INC | $134.8M | 2.35% |
| 6 | PTCT PTC THERAPEUTICS INC | $129.6M | 2.26% |
| 7 | INCY INCYTE CORP | $113.4M | 1.98% |
| 8 | FRPT FRESHPET INC | $112.7M | 1.97% |
| 9 | BIIB BIOGEN INC | $110.8M | 1.93% |
| 10 | NBIX NEUROCRINE BIOSCIENCES INC | $107.5M | 1.88% |
| 11 | GSK GSK PLC | $107.4M | 1.87% |
| 12 | AMZN AMAZON COM INC | $97.8M | 1.71% |
| 13 | ENTA ENANTA PHARMACEUTICALS INC | $96.7M | 1.69% |
| 14 | GOOGL ALPHABET INC | $86.1M | 1.5% |
| 15 | DCPH DECIPHERA PHARMACEUTICALS IN | $84.8M | 1.48% |
| 16 | REGN REGENERON PHARMACEUTICALS | $79.4M | 1.38% |
| 17 | AGIO AGIOS PHARMACEUTICALS INC | $77.2M | 1.35% |
| 18 | EXAS EXACT SCIENCES CORP | $76.0M | 1.33% |
| 19 | ALKS ALKERMES PLC | $75.8M | 1.32% |
| 20 | PCRX PACIRA BIOSCIENCES INC | $73.1M | 1.27% |
Values as reported on the Q4 2022 Form 13F. Every position is in the holdings table below.